
Sign up to save your podcasts
Or

Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.
Dr. Nasser Hanna discusses the SQUIRE trial of the EGFR antibody Necitumumab in patients with squamous lung cancer. Though it achieved a statistical increase in OS, he does not consider it clinically relevant.

2 Listeners

1 Listeners

0 Listeners
0 Listeners
1 Listeners

1 Listeners
0 Listeners
0 Listeners
0 Listeners